ONCS issues annual letter to shareholders
Jun 17, 2015 23:04:12 GMT
actcfan, RLC, and 2 more like this
Post by JHam on Jun 17, 2015 23:04:12 GMT
Nothing earth shattering, but the quote below strongly suggests P2b enrollment is just around the corner:
ir.oncosec.com/press-releases/detail/1829
OncoSec Medical Issues Annual Letter To Shareholders
"Our Phase II trial results in metastatic melanoma has led to an exciting new collaboration with the University of California, San Francisco, who will now be testing the hypothesis that ImmunoPulse™ IL-12 can enhance response to Merck's anti-PD-1 treatment, KEYTRUDA® (pembrolizumab)."
ir.oncosec.com/press-releases/detail/1829
OncoSec Medical Issues Annual Letter To Shareholders
"Our Phase II trial results in metastatic melanoma has led to an exciting new collaboration with the University of California, San Francisco, who will now be testing the hypothesis that ImmunoPulse™ IL-12 can enhance response to Merck's anti-PD-1 treatment, KEYTRUDA® (pembrolizumab)."